-
公开(公告)号：US20220387448A1
公开(公告)日：2022-12-08
申请号：US17843506
申请日：2022-06-17
摘要： The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml or about 160 mg/ml to 240 mg/ml medroxyprogesterone acetate, 1.2 mg/ml to 3.0 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
-
公开(公告)号：US20220331570A1
公开(公告)日：2022-10-20
申请号：US17638664
申请日：2020-08-30
发明人： Avshalom BEN MENACHEM , Ilan ZALIT
IPC分类号： A61M31/00
摘要： The present disclosure provides with a device for temporary residence at an ileocecal valve of a subject, the device having a trapping configuration, wherein in the trapping configuration, the device is configured to be retained at the ileocecal valve of the subject when the device is positioned at the ileocecal valve; comprises a trapping assembly configured for blocking a cooperating ingestible object while allowing chyme flow, when the device is positioned at the ileocecal valve; and the device being further configured to transfer from the trapping configuration into an emptying configuration in which the device is configured to pass through the ileocecal valve. The present disclosure further provides with oral dosage forms cooperating with the device for local dispensing of a therapeutic agent at the ileocecal valve region.
-
公开(公告)号：US10071206B2
公开(公告)日：2018-09-11
申请号：US15691380
申请日：2017-08-30
发明人： Toby Cowe
CPC分类号： A61M5/31595 , A61M5/20 , A61M5/2033 , A61M5/3157 , A61M5/3204 , A61M5/46 , A61M2005/202 , A61M2005/206 , A61M2005/2073 , A61M2005/208 , A61M2005/2086 , A61M2005/3125 , A61M2005/3126 , A61M2205/581 , A61M2205/583 , A61M2205/586
摘要： An injector device includes an injector body that receives a syringe; and an injection assembly being configured to dispense medicament from the syringe in a dispensation step. Certain types of injector devices include a sudden completion indicator that indicates when the injection is completed. Certain types of injector devices are configured to dispense two different medicament formulations having different viscosities from syringes without making any changes to the injector devices other than to switch out the syringes. Certain types of injector devices include safety arrangements that inhibit firing of the injector device until front and rear housing assemblies are disposed in predetermined rotational and axial positions relative to each other.
-
公开(公告)号：US20180250284A1
公开(公告)日：2018-09-06
申请号：US15758098
申请日：2016-09-08
申请人： GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN , TEVA PHARMACEUTICAL INDUSTRIES LTD.
IPC分类号： A61K31/4704 , A61K9/00
CPC分类号： A61K31/4704 , A61K9/0053 , C07D217/26
摘要： The present invention relates in a first aspect to compounds for use in the treatment of leukodystrophy whereby these compounds are quinoline derivatives, e.g. laquinimod. In a further aspect, the present invention relates to methods for the treatment of Leukodystrophy, in particular, peroxisomal disorders including Zellweger syndrome.
-
5.发明申请公开(公告)号：US20180140592A1
公开(公告)日：2018-05-24
申请号：US15861952
申请日：2018-01-04
发明人： Ulf Tomas Fristedt
IPC分类号： A61K31/4704 , C07D215/56 , A61K31/47 , A61K9/20
CPC分类号： A61K31/4704 , A61K9/20 , A61K31/47 , C07D215/56 , A61K2300/00
摘要： The subject invention provides 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses.
-
公开(公告)号：US20160296473A1
公开(公告)日：2016-10-13
申请号：US15185204
申请日：2016-06-17
CPC分类号： A61K9/1676 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/1682 , A61K31/52 , A61K31/522 , B01J2/16
摘要： The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
-
7.发明申请UNIT DOSAGE FORM COMPRISING EMTRICITABINE, TENOFOVIR, DARUNAVIR AND RITONAVIR AND A MONOLITHIC TABLET COMPRISING DARUNAVIR AND RITONAVIR 审中-公开包含EMTRICITABINE，TENOFOVIR，DARUNAVIR和RITONAVIR的单位剂型和包含DARUNAVIR和RITONAVIR的单片公开(公告)号：US20160199396A1
公开(公告)日：2016-07-14
申请号：US15051381
申请日：2016-02-23
发明人： Nitzan SHAHAR , Elina HARONSKY , Julia HRAKOVSKY
IPC分类号： A61K31/675 , A61K9/20 , A61K31/427 , A61K9/28 , A61K31/513 , A61K31/635
CPC分类号： A61K31/675 , A61K9/209 , A61K31/427 , A61K31/513 , A61K31/635 , A61K2300/00
摘要： The present invention relates to an oral unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and their use to treat HIV infection.
摘要翻译： 本发明涉及包含艾曲他滨，替诺福韦，达拉那韦和利托那韦的口服单位剂型，以及包含达鲁那韦和利托那韦的整体片剂及其用于治疗HIV感染的用途。
-
公开(公告)号：US09180097B2
公开(公告)日：2015-11-10
申请号：US14177037
申请日：2014-02-10
IPC分类号： A61K31/33 , A61K31/52 , A61K31/522 , A61K9/16
CPC分类号： A61K9/1676 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/1682 , A61K31/52 , A61K31/522 , B01J2/16
摘要： The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
摘要翻译： 本发明提供6-巯基嘌呤的改进制剂，其表现出比以前制剂更好的生物利用度和更快的溶解度。
-
公开(公告)号：US20150290133A1
公开(公告)日：2015-10-15
申请号：US14749857
申请日：2015-06-25
CPC分类号： A61K9/1676 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/1682 , A61K31/52 , A61K31/522 , B01J2/16
摘要： The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
摘要翻译： 本发明提供6-巯基嘌呤的改进制剂，其表现出比以前制剂更好的生物利用度和更快的溶解度。
-
10.发明授权Method of treatment for neutropenia using stable formulations of recombinant human albumin-human granulocyte colony stimulating factor 有权使用重组人白蛋白 - 人粒细胞集落刺激因子的稳定制剂治疗中性粒细胞减少症的方法公开(公告)号：US08993519B2
公开(公告)日：2015-03-31
申请号：US13660915
申请日：2012-10-25
发明人： Jason Benjamin Bock , Xia Luo
CPC分类号： A61K38/385 , A61K38/193 , A61K38/38 , A61K47/643
摘要： Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.
摘要翻译： 本文描述了用于治疗，预防和改善特征在于低于正常白细胞计数（例如白细胞减少和中性粒细胞减少）的疾病和病症的组合物和方法。 组合物和方法包括重组人白蛋白 - 人粒细胞集落刺激因子。 还描述了包括重组融合蛋白的药物制剂和制备这些制剂的方法。
-
-
-
-
-
-
-
-
-
搜索结果
79 条记录 (耗时 0.044 秒)
